This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
by Kinjel Shah
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
by Kanishka Das
MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
by Zacks Equity Research
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
by Kinjel Shah
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
The Zacks Analyst Blog Highlights Visa, Merck, Southern Company, Community Bancorp and Comstock
by Zacks Equity Research
V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.
Top Analyst Reports for Visa, Merck & Southern Company
by Mark Vickery
Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Here's Why Merck (MRK) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.